Montreal, September 2, 2025 — Leads & Copy — Theratechnologies Inc. is encouraging shareholders to vote “FOR” the arrangement with CB Biotechnology, LLC, an affiliate of Future Pak, LLC. Proxy advisory firms ISS and Glass Lewis have also recommended shareholders vote in favor of the special resolution.
Under the arrangement, the Purchaser will acquire all issued and outstanding common shares of Theratechnologies for US$3.01 per share in cash, plus one contingent value right (CVR) per share. The CVRs allow for potential additional cash payments of up to US$1.19 per CVR if specific company milestones are met.
ISS recommends voting FOR the arrangement, citing the “sizeable cash premium, additional upside from the CVRs, robust process, credible valuation, and non-approval risk.” Glass Lewis also supports the transaction, noting that the company undertook a reasonably extensive review process. The Theratechnologies board of directors unanimously recommends shareholders vote FOR the arrangement at the special meeting.
The meeting will be held in a hybrid format on Friday, September 12, 2025, at 10:00 a.m. (Eastern time), both in person at Fasken Martineau DuMoulin LLP in Montreal and virtually via live audio webcast at https://meetnow.global/MDUWLGW. Shareholders are encouraged to review the circular and submit proxies before the 10:00 a.m. (Eastern time) September 10, 2025 deadline.
Questions or need assistance? Contact Laurel Hill Advisory Group at 1-877-452-7184 or email assistance@laurelhill.com.
Contact:
Philippe Dubuc
438-315-6608
Julie Schneiderman
514-336-7800
Source: Theratechnologies Inc.
